179 related articles for article (PubMed ID: 30340213)
1. Association between bivariate expression of key oncogenes and metabolic phenotypes of patients with prostate cancer.
Khodayari Moez E; Pyne S; Dinu I
Comput Biol Med; 2018 Dec; 103():55-63. PubMed ID: 30340213
[TBL] [Abstract][Full Text] [Related]
2. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer.
Priolo C; Pyne S; Rose J; Regan ER; Zadra G; Photopoulos C; Cacciatore S; Schultz D; Scaglia N; McDunn J; De Marzo AM; Loda M
Cancer Res; 2014 Dec; 74(24):7198-204. PubMed ID: 25322691
[TBL] [Abstract][Full Text] [Related]
3. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Ren S; Shao Y; Zhao X; Hong CS; Wang F; Lu X; Li J; Ye G; Yan M; Zhuang Z; Xu C; Xu G; Sun Y
Mol Cell Proteomics; 2016 Jan; 15(1):154-63. PubMed ID: 26545398
[TBL] [Abstract][Full Text] [Related]
4. Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma.
Andersen MK; Rise K; Giskeødegård GF; Richardsen E; Bertilsson H; Størkersen Ø; Bathen TF; Rye M; Tessem MB
Sci Rep; 2018 Sep; 8(1):14269. PubMed ID: 30250137
[TBL] [Abstract][Full Text] [Related]
5. IntLIM: integration using linear models of metabolomics and gene expression data.
Siddiqui JK; Baskin E; Liu M; Cantemir-Stone CZ; Zhang B; Bonneville R; McElroy JP; Coombes KR; Mathé EA
BMC Bioinformatics; 2018 Mar; 19(1):81. PubMed ID: 29506475
[TBL] [Abstract][Full Text] [Related]
6. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer.
Meller S; Meyer HA; Bethan B; Dietrich D; Maldonado SG; Lein M; Montani M; Reszka R; Schatz P; Peter E; Stephan C; Jung K; Kamlage B; Kristiansen G
Oncotarget; 2016 Jan; 7(2):1421-38. PubMed ID: 26623558
[TBL] [Abstract][Full Text] [Related]
7. Metabolite Analysis and Histology on the Exact Same Tissue: Comprehensive Metabolomic Profiling and Metabolic Classification of Prostate Cancer.
Huan T; Troyer DA; Li L
Sci Rep; 2016 Aug; 6():32272. PubMed ID: 27578275
[TBL] [Abstract][Full Text] [Related]
8. Topologically inferring pathway activity toward precise cancer classification via integrating genomic and metabolomic data: prostate cancer as a case.
Liu W; Bai X; Liu Y; Wang W; Han J; Wang Q; Xu Y; Zhang C; Zhang S; Li X; Ren Z; Zhang J; Li C
Sci Rep; 2015 Aug; 5():13192. PubMed ID: 26286638
[TBL] [Abstract][Full Text] [Related]
9. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
[TBL] [Abstract][Full Text] [Related]
10. Comparative Metabolomic and Lipidomic Analysis of Phenotype Stratified Prostate Cells.
Burch TC; Isaac G; Booher CL; Rhim JS; Rainville P; Langridge J; Baker A; Nyalwidhe JO
PLoS One; 2015; 10(8):e0134206. PubMed ID: 26244785
[TBL] [Abstract][Full Text] [Related]
11. Oncogenes in prostate cancer. An update.
Peehl DM
Cancer; 1993 Feb; 71(3 Suppl):1159-64. PubMed ID: 8428339
[TBL] [Abstract][Full Text] [Related]
12. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics approaches and applications in prostate cancer research.
Zhang A; Yan G; Han Y; Wang X
Appl Biochem Biotechnol; 2014 Sep; 174(1):6-12. PubMed ID: 24838846
[TBL] [Abstract][Full Text] [Related]
14. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
15. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
Pan H; Zhu Y; Wei W; Shao S; Rui X
World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
Wang J; Yang X; Li R; Wang L; Gu Y; Zhao Y; Huang KH; Cheng T; Yuan Y; Gao S
Oncol Rep; 2018 Nov; 40(5):2814-2825. PubMed ID: 30132573
[TBL] [Abstract][Full Text] [Related]
17. Innovation in metabolomics to improve personalized healthcare.
Cacciatore S; Loda M
Ann N Y Acad Sci; 2015 Jun; 1346(1):57-62. PubMed ID: 26014591
[TBL] [Abstract][Full Text] [Related]
18. MSD-MAP: A Network-Based Systems Biology Platform for Predicting Disease-Metabolite Links.
Wathieu H; Issa NT; Mohandoss M; Byers SW; Dakshanamurthy S
Comb Chem High Throughput Screen; 2017; 20(3):193-207. PubMed ID: 28024464
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
Hawksworth D; Ravindranath L; Chen Y; Furusato B; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5. PubMed ID: 20820186
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
